The xenograft tumor models of CEACAM6‐positive (A549) and CEACAM6‐negative (Huh7) were established to further assess the specificity of 89Zr‐Df‐tinurilimab in targeting CEACAM6‐positive tumors in vivo. This evidence concerns the gene CEACAM6 and neoplasm.